VIB VERMOEGEN AG (VIH1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VIH1 - DE000A2YPDD0 - Common Stock
10.3 EUR
+0.05 (+0.49%)
Overall VIH1 gets a fundamental rating of 5 out of 10. We evaluated VIH1 against 77 industry peers in the Real Estate Management & Development industry. There are concerns on the financial health of VIH1 while its profitability can be described as average. VIH1 is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
VIH1 had positive earnings in the past year.
In the past year VIH1 had a positive cash flow from operations.
VIH1 had positive earnings in each of the past 5 years.
In the past 5 years VIH1 always reported a positive cash flow from operatings.
1.2 Ratios
VIH1 has a Return On Assets (1.69%) which is comparable to the rest of the industry.
VIH1 has a Return On Equity of 3.99%. This is comparable to the rest of the industry: VIH1 outperforms 58.44% of its industry peers.
VIH1's Return On Invested Capital of 3.21% is fine compared to the rest of the industry. VIH1 outperforms 67.53% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VIH1 is in line with the industry average of 3.90%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.69% | ||
| ROE | 3.99% | ||
| ROIC | 3.21% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
1.3 Margins
VIH1's Profit Margin of 34.63% is fine compared to the rest of the industry. VIH1 outperforms 72.73% of its industry peers.
VIH1's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 70.15%, VIH1 belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
VIH1's Operating Margin has declined in the last couple of years.
The Gross Margin of VIH1 (78.88%) is better than 68.83% of its industry peers.
VIH1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% |
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
2. Health
2.1 Basic Checks
VIH1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for VIH1 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, VIH1 has more shares outstanding
The debt/assets ratio for VIH1 has been reduced compared to a year ago.
2.2 Solvency
VIH1 has an Altman-Z score of 0.70. This is a bad value and indicates that VIH1 is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.70, VIH1 is doing worse than 68.83% of the companies in the same industry.
The Debt to FCF ratio of VIH1 is 10.39, which is on the high side as it means it would take VIH1, 10.39 years of fcf income to pay off all of its debts.
VIH1 has a Debt to FCF ratio of 10.39. This is in the better half of the industry: VIH1 outperforms 72.73% of its industry peers.
A Debt/Equity ratio of 1.01 is on the high side and indicates that VIH1 has dependencies on debt financing.
The Debt to Equity ratio of VIH1 (1.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 10.39 | ||
| Altman-Z | 0.7 |
ROIC/WACC0.73
WACC4.42%
2.3 Liquidity
VIH1 has a Current Ratio of 1.03. This is a normal value and indicates that VIH1 is financially healthy and should not expect problems in meeting its short term obligations.
VIH1 has a worse Current ratio (1.03) than 61.04% of its industry peers.
A Quick Ratio of 1.03 indicates that VIH1 should not have too much problems paying its short term obligations.
VIH1's Quick ratio of 1.03 is in line compared to the rest of the industry. VIH1 outperforms 59.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The earnings per share for VIH1 have decreased strongly by -72.11% in the last year.
Measured over the past years, VIH1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.74% on average per year.
The Revenue has been growing slightly by 4.50% in the past year.
Measured over the past years, VIH1 shows a small growth in Revenue. The Revenue has been growing by 2.78% on average per year.
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
3.2 Future
Based on estimates for the next years, VIH1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.54% on average per year.
Based on estimates for the next years, VIH1 will show a quite strong growth in Revenue. The Revenue will grow by 10.81% on average per year.
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.45, the valuation of VIH1 can be described as reasonable.
Based on the Price/Earnings ratio, VIH1 is valued a bit cheaper than 76.62% of the companies in the same industry.
VIH1 is valuated cheaply when we compare the Price/Earnings ratio to 26.76, which is the current average of the S&P500 Index.
VIH1 is valuated cheaply with a Price/Forward Earnings ratio of 4.72.
Based on the Price/Forward Earnings ratio, VIH1 is valued cheaply inside the industry as 94.81% of the companies are valued more expensively.
VIH1's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.96.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.45 | ||
| Fwd PE | 4.72 |
4.2 Price Multiples
VIH1's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VIH1 is cheaper than 93.51% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, VIH1 is valued cheaply inside the industry as 89.61% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.43 | ||
| EV/EBITDA | 6.35 |
4.3 Compensation for Growth
VIH1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VIH1 may justify a higher PE ratio.
PEG (NY)0.9
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VIH1 has a yearly dividend return of 0.39%, which is pretty low.
VIH1's Dividend Yield is comparable with the industry average which is at 7.45.
With a Dividend Yield of 0.39, VIH1 pays less dividend than the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.39% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y11.54%
EPS Next 3YN/A
FRA:VIH1 (12/11/2025, 7:00:00 PM)
10.3
+0.05 (+0.49%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)
Earnings (Next)
Inst Owners0.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap340.41M
Revenue(TTM)104.37M
Net Income(TTM)36.14M
Analysts82.86
Price Target11.73 (13.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.39% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.45 | ||
| Fwd PE | 4.72 | ||
| P/S | 3.26 | ||
| P/FCF | 3.43 | ||
| P/OCF | 3.43 | ||
| P/B | 0.38 | ||
| P/tB | 0.39 | ||
| EV/EBITDA | 6.35 |
EPS(TTM)1.09
EY10.58%
EPS(NY)2.18
Fwd EY21.19%
FCF(TTM)3.01
FCFY29.18%
OCF(TTM)3.01
OCFY29.18%
SpS3.16
BVpS27.39
TBVpS26.47
PEG (NY)0.9
PEG (5Y)N/A
Graham Number25.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.69% | ||
| ROE | 3.99% | ||
| ROCE | 3.73% | ||
| ROIC | 3.21% | ||
| ROICexc | 3.25% | ||
| ROICexgc | 3.3% | ||
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% | ||
| FCFM | 95.17% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
ROICexc(3y)4.4%
ROICexc(5y)4.63%
ROICexgc(3y)4.52%
ROICexgc(5y)4.7%
ROCE(3y)4.69%
ROCE(5y)5.03%
ROICexgc growth 3Y-10.75%
ROICexgc growth 5Y-3.98%
ROICexc growth 3Y-11.34%
ROICexc growth 5Y-4.36%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 10.39 | ||
| Debt/EBITDA | 4.3 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 46.63% | ||
| Profit Quality | 274.83% | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 0.7 |
F-Score4
WACC4.42%
ROIC/WACC0.73
Cap/Depr(3y)0.86%
Cap/Depr(5y)88.75%
Cap/Sales(3y)0.31%
Cap/Sales(5y)0.52%
Profit Quality(3y)144.88%
Profit Quality(5y)156.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.54%
EBIT growth 3Y-3.27%
EBIT growth 5Y0.72%
EBIT Next Year69.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.92%
FCF growth 3Y6.73%
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3Y6.76%
OCF growth 5Y5.7%
VIB VERMOEGEN AG / VIH1.DE FAQ
What is the fundamental rating for VIH1 stock?
ChartMill assigns a fundamental rating of 5 / 10 to VIH1.DE.
What is the valuation status for VIH1 stock?
ChartMill assigns a valuation rating of 8 / 10 to VIB VERMOEGEN AG (VIH1.DE). This can be considered as Undervalued.
What is the profitability of VIH1 stock?
VIB VERMOEGEN AG (VIH1.DE) has a profitability rating of 6 / 10.
What is the earnings growth outlook for VIB VERMOEGEN AG?
The Earnings per Share (EPS) of VIB VERMOEGEN AG (VIH1.DE) is expected to grow by 10.47% in the next year.